Xeloda

E238181

Xeloda is an oral chemotherapy drug (capecitabine) commonly used to treat various cancers, including colorectal and breast cancer.

All labels observed (1)

Label Occurrences
Xeloda canonical 1

How this entity was disambiguated

Statements (57)

Predicate Object
instanceOf antimetabolite
chemotherapy drug
fluoropyrimidine
pharmaceutical drug
hasActiveIngredient capecitabine
hasApprovalAgency European Medicines Agency
Food and Drug Administration
surface form: U.S. Food and Drug Administration
hasATCCode L01BC06
hasBlackBoxWarning may cause serious and fatal adverse reactions similar to fluorouracil
hasCommonSideEffect abdominal pain
anorexia
diarrhea
fatigue
hand‑foot syndrome
nausea
rash
stomatitis
vomiting
hasDosageForm film‑coated tablet
hasGenericName capecitabine
hasMechanismOfAction inhibits DNA synthesis in rapidly dividing cells
interferes with RNA processing and function
prodrug of 5‑fluorouracil
hasPregnancyCategory D (US, historical classification)
hasRouteOfAdministration oral
hasSeriousAdverseEffect cardiotoxicity
hepatic dysfunction
myelosuppression
severe diarrhea
severe skin reactions
hasTypicalDosingSchedule twice daily for 14 days followed by 7 days rest in 21‑day cycles
interactsWith folinic acid (leucovorin)
phenytoin
warfarin
isActivatedPreferentiallyIn tumor tissue
isAvailableAs brand‑name drug
generic drug
isContraindicatedIn known hypersensitivity to capecitabine
known hypersensitivity to fluorouracil
severe renal impairment
isConvertedTo 5‑fluorouracil
isIndicatedFor adjuvant treatment of colon cancer
breast cancer
colorectal cancer
metastatic breast cancer
metastatic colorectal cancer
isIndicatedForUseWith docetaxel in metastatic breast cancer after anthracycline failure
isManufacturedBy Roche
surface form: Hoffmann‑La Roche
isMetabolizedPrimarilyIn liver
isTeratogenic true
isUsedAs combination therapy in colorectal cancer
monotherapy in colorectal cancer
monotherapy in metastatic breast cancer
requiresDoseAdjustmentIn renal impairment
shouldBeUsedWithCautionIn elderly patients
patients with cardiac disease
wasFirstApprovedIn 1998

How these facts were elicited

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

Roche product Xeloda